Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD.

Antivir Ther. 2008;13(2):177-87.

PMID:
18505169
2.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team.

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18.

PMID:
22805174
3.
4.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
5.

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.

Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, Autran B, Katlama C.

AIDS. 1999 Apr 16;13(6):677-83.

PMID:
10397562
6.

A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.

Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA.

Clin Infect Dis. 2005 Feb 15;40(4):594-600. Epub 2005 Jan 26.

PMID:
15712083
7.

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team.

BMC Infect Dis. 2005 Jan 12;5:2.

8.

HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.

Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B.

Int J STD AIDS. 2007 Dec;18(12):832-4.

PMID:
18073016
9.

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team.

PLoS One. 2013 Oct 30;8(10):e77138. doi: 10.1371/journal.pone.0077138. eCollection 2013.

10.

Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.

Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.

J Infect. 2007 Feb;54(2):159-66. Epub 2006 May 11.

PMID:
16690132
11.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
12.

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugyenyi P, Gibb DM, Gilks CF; DART/NORA trial teams.

HIV Med. 2010 May;11(5):334-44. doi: 10.1111/j.1468-1293.2009.00786.x. Epub 2010 Feb 3.

13.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

14.

Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.

Lampe FC, Duprez DA, Kuller LH, Tracy R, Otvos J, Stroes E, Cooper DA, Hoy J, Paton NI, Friis-Møller N, Neuhaus J, Liappis AP, Phillips AN; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2010 Jul;54(3):275-84.

15.

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

Clin Infect Dis. 2008 Mar 15;46(6):933-40. doi: 10.1086/528861.

PMID:
18271750
16.

A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).

Walmsley SL, Thorne A, Loutfy MR, LaPierre N, MacLeod J, Harrigan R, Trottier B, Conway B, Hay JR, Singer J, Zarowny D.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25.

PMID:
17468667
17.

CD4+ count-guided interruption of antiretroviral treatment.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

N Engl J Med. 2006 Nov 30;355(22):2283-96.

18.

Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.

Bonjoch A, Buzon MJ, Llibre JM, Negredo E, Puig J, Pérez-Alvarez N, Videla S, Martinez-Picado J, Clotet B.

HIV Clin Trials. 2008 Nov-Dec;9(6):387-98. doi: 10.1310/hct0906-387.

PMID:
19203904
19.

Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.

Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, Lazzarin A.

J Med Virol. 2004 Feb;72(2):181-6.

PMID:
14695657
20.

Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.

Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A, Poli G, Gotch F, Autran B.

Antivir Ther. 2007;12(4):553-8.

PMID:
17668564

Supplemental Content

Support Center